Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 3/20 | 0.46 |
| ▸ | REN | P00797 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4216552 | 1.00 | CTSS (0.56) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL4216541 | 1.00 | CTSS (0.56) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL9540730 | 0.88 | CTSS (0.61) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL9540722 | 0.88 | CTSS (0.61) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL22267923 | 0.86 | CTSS (0.68) | CTSSCTSKPSENENCA2 | |
| SCHEMBL19061547 | 0.85 | CTSK (0.67) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL4225806 | 0.85 | CTSK (0.67) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL4223929 | 0.84 | CTSD (0.63) | CTSKCTSBPSENENCTSDREN | |
| SCHEMBL4223933 | 0.84 | CTSD (0.63) | CTSKCTSBPSENENCTSDREN | |
| SCHEMBL4223930 | 0.84 | CTSD (0.63) | CTSKCTSBPSENENCTSDREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1498909-B1 | Dielectric substrate comprising a polyimide core layer and a high temperature fluoropolymer bonding layer, and methods relating thereto | DU PONT (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20090105091-A1 | Modified Amino Acids | TECHNISCHE UNIVERSITAT WIEN (AT) | 2009-04-23 | — | — | US | disclosed |
| EP-1989180-A1 | MODIFIED AMINO ACIDS | Technische Universität Wien (AT) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007095980-A1 | MODIFIED AMINO ACIDS | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2007-08-30 | — | — | WO | disclosed |
| EP-1826199-A1 | Modified amino acids | Technische Universität Wien (AT) | 2007-08-29 | — | — | EP | disclosed |
| US-7022402-B2 | Dielectric substrates comprising a polymide core layer and a high temperature fluoropolymer bonding layer, and methods relating thereto | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050013998-A1 | Dielectric substrates comprising a polymide core layer and a high temperature fluoropolymer bonding layer, and methods relating thereto | DUPONT ELECTRONICS, INC. | 2005-01-20 | — | — | US | disclosed |
| EP-1498909-A1 | Dielectric substrate comprising a polyimide core layer and a high temperature fluoropolymer bonding layer, and methods relating thereto | E.I. du Pont de Nemours and Company (US) | 2005-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105091-A1 | Modified Amino Acids | SLC1A2, NR1H4, OXGR1 | CTSS 4519/4885CTSK 4083/4885CTSL 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.